Effects of Budesonide Plus Vitamin AD on Children with Bronchial Asthma and the Effect on Serum IgE and C-reactive Protein

Objective: To investigate the efficacy of budesonide plus vitamin AD in children with bronchial asthma and the efect on serum IgE and C-reactive protein (CRP). Methods: In this retrospective analysis, 80 children with bronchial asthma treated in our hospital from October 2018 to October 2020 were recruited and assigned 1:1 to receive either vitamin AD (control group) or budesonide plus vitaminAD (study group), with 40 cases in each group. Results: Budesonide potentiated the treatment efcacy of vitamin AD by 17.5% (P<0.05). Patients receiving the combined therapy exhibited more reduction in the serum concentrations of IgE and CRP versus those with monotherapy of vitamin AD (P<0.05). Patients in the study group had lower bronchial asthma symptom scores than those in the control group, suggesting more symptom mitigation produced by budesonide plus vitamin AD (P<0.05). Budesonide plus vitamin AD ofered better lung function restoration for patients versus vitamin AD alone, as evinced by the superior lung function indices (P<0.05). Patients with budesonide plus vitaminAD experienced a shorter duration of symptoms versus controls (P<0.05). Conclusion: Budesonide plus vitaminAD exerts a promising clinical efcacy in treating children with bronchial asthma.